| Literature DB >> 29923599 |
Jan H Beumer1,2,3, Edward Chu1,3, Carmen Allegra4, Yusuke Tanigawara5, Gerard Milano6, Robert Diasio7,8, Tae Won Kim9, Ron H Mathijssen10, Li Zhang11, Dirk Arnold12, Katsuki Muneoka13, Narikazu Boku14, Markus Joerger15.
Abstract
5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29923599 PMCID： PMC6309286 DOI： 10.1002/cpt.1124
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875